Bullu
News
Events
NEW
Research
NEW
Talk to Us
FEEDBACK
Search stocks or news
Loading…
US Court Rules Against Lupin in Myrbetriq® Patent Case | Bullu
LUPIN
US Court Rules Against Lupin in Myrbetriq® Patent Case
Source
|
08:48 26 Apr 25
legal
regulatory filings
US Court ruled against Lupin in patent case filed by Astellas Pharma regarding generic Mirabegron (Myrbetriq®) on April 15, 2025.
The United States District Court for the District of Delaware upheld the validity of Astellas' U.S. Patent No. 10,842,780.
A jury trial is scheduled in 2026 to litigate issues of infringement, damages, and additional invalidity theories.
Lupin believes it has a strong case and is evaluating further legal action. Currently, no material financial implications are expected.
0
Subscribe
Ask Bullu
More Latest News